{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T21:27:50Z","timestamp":1773091670508,"version":"3.50.1"},"reference-count":92,"publisher":"Baishideng Publishing Group Inc.","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJH"],"published-print":{"date-parts":[[2010]]},"DOI":"10.4254\/wjh.v2.i9.325","type":"journal-article","created":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T09:24:19Z","timestamp":1285838659000},"page":"325","source":"Crossref","is-referenced-by-count":38,"title":["Current concepts on cytomegalovirus infection after liver transplantation"],"prefix":"10.4254","volume":"2","author":[{"given":"Sang-Oh","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","unstructured":"Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes 2004;11:77-86."},{"key":"ref2","unstructured":"Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003;10:60-65."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007;13:1703-1709.","DOI":"10.1002\/lt.21280"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Gane E, Saliba F, Valdecasas GJ, O’Grady J, Pescovitz MD, Lyman S, Robinson CA. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997;350:1729-1733.","DOI":"10.1016\/S0140-6736(97)05535-9"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-620.","DOI":"10.1111\/j.1600-6143.2004.00382.x"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-1097.","DOI":"10.1086\/339329"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Fica A, Cervera C, Pérez N, Marcos MA, Ramírez J, Linares L, Soto G, Navasa M, Cofan F, Ricart MJ. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests. Transpl Infect Dis 2007;9:203-210.","DOI":"10.1111\/j.1399-3062.2007.00220.x"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Paya CV, Hermans PE, Wiesner RH, Ludwig J, Smith TF, Rakela J, Krom RA. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis 1989;160:752-758.","DOI":"10.1093\/infdis\/160.5.752"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Razonable RR, van Cruijsen H, Brown RA, Wilson JA, Harmsen WS, Wiesner RH, Smith TF, Paya CV. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003;187:1801-1808.","DOI":"10.1086\/375194"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Singh N, Wagener MM. Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2006;144:456-457; author reply 457.","DOI":"10.7326\/0003-4819-144-6-200603210-00024"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection? Liver Transpl 2005;11:700-704.","DOI":"10.1002\/lt.20417"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005;62:S7-S13.","DOI":"10.1093\/ajhp\/62.suppl_1.S7"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001;184:1461-1464.","DOI":"10.1086\/324516"},{"key":"ref14","unstructured":"Razonable RR, Paya CV. Infections and allograft rejection - intertwined complications of organ transplantation. Swiss Med Wkly 2005;135:571-573."},{"key":"ref15","unstructured":"O’Grady JG, Alexander GJ, Sutherland S, Donaldson PT, Harvey F, Portmann B, Calne RY, Williams R. Cytomegalovirus infection and donor\/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 1988;2:302-305."},{"key":"ref16","unstructured":"Noack KB, Wiesner RH, Batts K, van Hoek B, Ludwig J. Severe ductopenic rejection with features of vanishing bile duct syndrome: clinical, biochemical, and histologic evidence for spontaneous resolution. Transplant Proc 1991;23:1448-1451."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Ludwig J, Wiesner RH, Batts KP, Perkins JD, Krom RA. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987;7:476-483.","DOI":"10.1002\/hep.1840070311"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Pastacaldi S, Teixeira R, Montalto P, Rolles K, Burroughs AK. Hepatic artery thrombosis after orthotopic liver transplantation: a review of nonsurgical causes. Liver Transpl 2001;7:75-81.","DOI":"10.1053\/jlts.2001.22040"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Madalosso C, de Souza NF Jr, Ilstrup DM, Wiesner RH, Krom RA. Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation 1998;66:294-297.","DOI":"10.1097\/00007890-199808150-00003"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Eid AJ, Razonable RR. Cytomegalovirus disease in solid organ transplant recipients: advances lead to new challenges and opportunities. Current Opinion in Organ Transplantation 2007;12:610-617.","DOI":"10.1097\/MOT.0b013e3282f0d386"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Peleg AY, Husain S, Qureshi ZA, Silveira FP, Sarumi M, Shutt KA, Kwak EJ, Paterson DL. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007;44:1307-1314.","DOI":"10.1086\/514340"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Mendez JC, Dockrell DH, Espy MJ, Smith TF, Wilson JA, Harmsen WS, Ilstrup D, Paya CV. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001;183:179-184.","DOI":"10.1086\/317929"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Dockrell DH, Prada J, Jones MF, Patel R, Badley AD, Harmsen WS, Ilstrup DM, Wiesner RH, Krom RA, Smith TF. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis 1997;176:1135-1140.","DOI":"10.1086\/514104"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Mendez J, Espy M, Smith TF, Wilson J, Wiesner R, Paya CV. Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. Transplantation 1998;65:1477-1481.","DOI":"10.1097\/00007890-199806150-00012"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Razonable RR, Rivero A, Brown RA, Hart GD, Espy MJ, van Cruijsen H, Wilson J, Groettum C, Kremers W, Smith TF. Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003;17:114-120.","DOI":"10.1034\/j.1399-0012.2003.02104.x"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Humar A, Washburn K, Freeman R, Paya CV, Mouas H, Alecock E, Razonable RR. An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transpl 2007;13:1422-1427.","DOI":"10.1002\/lt.21266"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, Mazzulli T. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002;2:461-466.","DOI":"10.1034\/j.1600-6143.2002.20511.x"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A, Orloff SL, Rabkin JM, Benner KG. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997;64:721-726.","DOI":"10.1097\/00007890-199709150-00010"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Razonable RR, Burak KW, van Cruijsen H, Brown RA, Charlton MR, Smith TF, Espy MJ, Kremers W, Wilson JA, Groettum C. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002;35:974-981.","DOI":"10.1086\/342911"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Singh N, Husain S, Carrigan DR, Knox KK, Weck KE, Wagener MM, Gayowski T. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant 2002;16:92-96.","DOI":"10.1034\/j.1399-0012.2002.1o096.x"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, Paya CV, Charlton MR. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8:362-369.","DOI":"10.1053\/jlts.2002.32282"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, Razonable RR. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008;46:840-846.","DOI":"10.1086\/528718"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, Kuhr CS, Levy AE, Perkins JD, Reyes JD. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006;81:1645-1652.","DOI":"10.1097\/01.tp.0000226071.12562.1a"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Hodson EM, Barclay PG, Craig JC, Jones C, Kable K, Strippoli GF, Vimalachandra D, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2005;CD003774.","DOI":"10.1002\/14651858.CD003774.pub2"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143:870-880.","DOI":"10.7326\/0003-4819-143-12-200512200-00005"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006;43:869-880.","DOI":"10.1086\/507337"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Portela D, Patel R, Larson-Keller JJ, Ilstrup DM, Wiesner RH, Steers JL, Krom RA, Paya CV. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995;171:1014-1018.","DOI":"10.1093\/infdis\/171.4.1014"},{"key":"ref38","unstructured":"Winston DJ, Imagawa DK, Holt CD, Kaldas F, Shaked A, Busuttil RW. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 1995;60:1357-1360."},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006;81:17-20.","DOI":"10.1097\/01.tp.0000189713.14993.db"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, Shutt KA, Shapiro R, Thai N, Abu-Elmagd K. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007;44:204-212.","DOI":"10.1086\/510388"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355:1967-1977.","DOI":"10.1056\/NEJMoa060068"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000;14:136-138.","DOI":"10.1034\/j.1399-0012.2000.140206.x"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Demopoulos L, Polinsky M, Steele G, Mines D, Blum M, Caulfield M, Adamkovic A, Liu Q, Harler MB, Hahn C. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 2008;40:1407-1410.","DOI":"10.1016\/j.transproceed.2008.03.084"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Vítko S, Margreiter R, Weimar W, Dantal J, Kuypers D, Winkler M, Øyen O, Viljoen HG, Filiptsev P, Sadek S. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005;5:2521-2530.","DOI":"10.1111\/j.1600-6143.2005.01063.x"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 2007;44:1315-1320.","DOI":"10.1086\/514339"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007;195:633-644.","DOI":"10.1086\/511307"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, Venkataraman S, Humar A. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009;9:1214-1222.","DOI":"10.1111\/j.1600-6143.2009.02618.x"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"La Rosa C, Krishnan A, Longmate J, Martinez J, Manchanda P, Lacey SF, Limaye AP, Diamond DJ. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis 2008;197:25-33.","DOI":"10.1086\/523652"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Humar A, Mazzulli T, Moussa G, Razonable RR, Paya CV, Pescovitz MD, Covington E, Alecock E. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+\/R- transplant recipients. Am J Transplant 2005;5:1065-1070.","DOI":"10.1111\/j.1600-6143.2005.00797.x"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Warlé MC, Farhan A, Metselaar HJ, Hop WC, van der Plas AJ, Kap M, de Rave S, Kwekkeboom J, Zondervan PE, IJzermans JN. In vitro cytokine production of TNFalpha and IL-13 correlates with acute liver transplant rejection. Hum Immunol 2001;62:1258-1265.","DOI":"10.1016\/S0198-8859(01)00321-4"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Fietze E, Prösch S, Reinke P, Stein J, Döcke WD, Staffa G, Löning S, Devaux S, Emmrich F, von Baehr R. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994;58:675-680.","DOI":"10.1097\/00007890-199409000-00007"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Cook CH, Trgovcich J, Zimmerman PD, Zhang Y, Sedmak DD. Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice. J Virol 2006;80:9151-9158.","DOI":"10.1128\/JVI.00216-06"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Hooks MA, Perlino CA, Henderson JM, Millikan WJ Jr, Kutner MH. Prevalence of invasive cytomegalovirus disease with administration of muromonab CD-3 in patients undergoing orthotopic liver transplantation. Ann Pharmacother 1992;26:617-620.","DOI":"10.1177\/106002809202600501"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Singh N, Gayowski T, Wagener MM, Marino IR. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 1996;61:402-406.","DOI":"10.1097\/00007890-199602150-00014"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000;355:2032-2036.","DOI":"10.1016\/S0140-6736(00)02350-3"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Mattes FM, Hainsworth EG, Hassan-Walker AF, Burroughs AK, Sweny P, Griffiths PD, Emery VC. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005;191:89-92.","DOI":"10.1086\/425905"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol 2006;35:474-477.","DOI":"10.1016\/j.jcv.2005.10.014"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF, Patel R, Jenkins G, Harmsen WS, Vanness DJ. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002;185:854-860.","DOI":"10.1086\/339449"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005;79:85-90.","DOI":"10.1097\/01.TP.0000146844.65273.62"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation 2000;70:717-722.","DOI":"10.1097\/00007890-200009150-00002"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Singh N, Yu VL. Preemptive therapy for cytomegalovirus. Liver Transpl 2006;12:327.","DOI":"10.1002\/lt.20676"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009;9 Suppl 4:S78-S86.","DOI":"10.1111\/j.1600-6143.2009.02897.x"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar A. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779-795.","DOI":"10.1097\/TP.0b013e3181cee42f"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008;8:158-161.","DOI":"10.1111\/j.1600-6143.2007.02026.x"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Vandecasteele E, De Waele J, Vandijck D, Blot S, Vogelaers D, Rogiers X, Van Vlierberghe H, Decruyenaere J, Hoste E. Antimicrobial prophylaxis in liver transplant patients--a multicenter survey endorsed by the European Liver and Intestine Transplant Association. Transpl Int 2010;23:182-190.","DOI":"10.1111\/j.1432-2277.2009.00974.x"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Singh N, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, Cacciarelli TV. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transpl 2008;14:240-244.","DOI":"10.1002\/lt.21362"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Caliendo AM, St George K, Kao SY, Allega J, Tan BH, LaFontaine R, Bui L, Rinaldo CR. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J Clin Microbiol 2000;38:2122-2127.","DOI":"10.1128\/JCM.38.6.2122-2127.2000"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, Vimalachandra D, Craig JC. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005;365:2105-2115.","DOI":"10.1016\/S0140-6736(05)66553-1"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005;79:1428-1434.","DOI":"10.1097\/01.TP.0000157867.98649.F5"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995;346:69-74.","DOI":"10.1016\/S0140-6736(95)92110-9"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Paya CV, Hermans PE, Smith TF, Rakela J, Wiesner RH, Krom RA, Torres VE, Sterioff S, Wilkowske CJ. Efficacy of ganciclovir in liver and kidney transplant recipients with severe cytomegalovirus infection. Transplantation 1988;46:229-234.","DOI":"10.1097\/00007890-198808000-00008"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Winston DJ, Busuttil RW. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 2003;75:229-233.","DOI":"10.1097\/01.TP.0000040601.60276.96"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti Infect Ther 2004;2:27-41.","DOI":"10.1586\/14787210.2.1.27"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004;189:1615-1618.","DOI":"10.1086\/382753"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002;35:866-872.","DOI":"10.1086\/342385"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, O’Grady J, Robinson C, To Z, Wren K. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000;44:2811-2815.","DOI":"10.1128\/AAC.44.10.2811-2815.2000"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant Proc 2005;37:3182-3186.","DOI":"10.1016\/j.transproceed.2005.07.032"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Freeman RB, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Heaton N. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004;78:1765-1773.","DOI":"10.1097\/01.TP.0000142619.01510.A5"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007;7:2106-2113.","DOI":"10.1111\/j.1600-6143.2007.01910.x"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Humar A, Paya C, Pescovitz MD, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Mueller B. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+\/R- solid organ transplant recipients. Am J Transplant 2004;4:644-649.","DOI":"10.1111\/j.1600-6143.2004.00391.x"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000;181:717-720.","DOI":"10.1086\/315242"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Jang EY, Park SY, Lee EJ, Song EH, Chong YP, Lee SO, Choi SH, Woo JH, Kim YS, Kim SH. Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. Clin Infect Dis 2009;48:e121-e124.","DOI":"10.1086\/599116"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Eid AJ, Bakri SJ, Kijpittayarit S, Razonable RR. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis 2008;10:13-18.","DOI":"10.1111\/j.1399-3062.2007.00241.x"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Eid AJ, Razonable RR. Valganciclovir for the treatment of cytomegalovirus retinitis in patients with AIDS. Expert Review of Ophthalmology 2007;2:351-361.","DOI":"10.1586\/17469899.2.3.351"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010;10:157-161.","DOI":"10.1111\/j.1600-6143.2009.02861.x"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Limaye AP. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Semin Respir Infect 2002;17:265-273.","DOI":"10.1053\/srin.2002.36447"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Chou S, Wechel LC, Marousek GI. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis 2007;196:91-94.","DOI":"10.1086\/518514"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008;18:233-246.","DOI":"10.1002\/rmv.574"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008;22:162-170.","DOI":"10.1111\/j.1399-0012.2007.00761.x"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Shapira MY, Resnick IB, Chou S, Neumann AU, Lurain NS, Stamminger T, Caplan O, Saleh N, Efferth T, Marschall M. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008;46:1455-1457.","DOI":"10.1086\/587106"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Maribavir: 1263W94, Benzimidavir , GW 1263, GW 1263W94, VP41263 . Drugs R D 2007;8:188-192.","DOI":"10.2165\/00126839-200708030-00006"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, Alangaden GJ, Chemaly RF, Petersen F, Chao N. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008;111:5403-5410.","DOI":"10.1182\/blood-2007-11-121558"}],"container-title":["World Journal of Hepatology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T15:02:19Z","timestamp":1685804539000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v2\/i9\/325.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":92,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.4254\/wjh.v2.i9.325","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]}}}